Standard Biotools is trading 5.7% lower at $0.70 after the October 2, 2026 regular-session close of $0.74; no clear company-specific announcement explaining the after-hours decline was found.
- The latest company announcement located was dated September 30 and concerned a new purchase agreement for its Mass Cytometry business with Element Biosystems, after the company determined GMT Venture’s proposal was superior.
- Available sources do not establish that this earlier news caused the after-hours move.